Journal article
Going viral with cancer immunotherapy
Abstract
Oncolytic viruses were originally designed as tumour-lysing therapeutics. However, they also initiate systemic antitumour immune responses. Can these viruses be exploited to enhance antitumour immune responses, and how might they be combined with other cancer immunotherapies?
Authors
Lichty BD; Breitbach CJ; Stojdl DF; Bell JC
Journal
Nature Reviews Cancer, Vol. 14, No. 8, pp. 559–567
Publisher
Springer Nature
Publication Date
August 2014
DOI
10.1038/nrc3770
ISSN
1474-175X